Skip to main content

Advertisement

SpringerLink
Log in

Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

We investigated the association between fibroblast growth factor-23 (FGF-23) and (1) the biochemical parameters implicated in chronic kidney disorder (CKD)-bone and mineral disorder (CKD-MBD) and (2) bone mineral density (BMD) in patients with CKD 1-4. C-reactive protein (CRP) and serum phosphate correlated with FGF-23. A significant association was seen between FGF-23 and BMD at the hip.

Introduction

Circulating FGF-23 is elevated in CKD, although the primary stimulus remains unclear. Moreover, it is still unknown whether increase in FGF-23 has a biological effect on bone metabolism. The aim of the study was to investigate the association of FGF-23 with (1) the biochemical parameters linked with CKD-bone and mineral disorder (CKD-MBD) and (2) bone mineral density in CKD.

Methods

We studied 145 patients (74 M, 71 F) aged (mean [SD]) 53 [14] years with CKD 1–4. Serum calcium, phosphate, parathyroid hormone, FGF-23, 25 (OH) vitamin D, 1, 25 (OH)2 vitamin D, bone turnover markers, CRP were determined. BMD was measured at the lumbar spine, femoral neck (FN), forearm, and total hip (TH). Multivariate analysis was undertaken to explore the association between (1) the biochemical variables and FGF-23 and (2) FGF-23 and BMD.

Results

Elevations in FGF-23 occurred in CKD stage 3 compared to CKD stage 1/2, although no significant differences in serum phosphate were observed. Serum phosphate (p < 0.001), CRP (p < 0.001) and diabetes mellitus (p < 0.05) were associated with FGF-23. BMD Z-score was significantly lower at the TH and FN in CKD 4 (p < 0.05). A significant association was seen between BMI, FGF-23, bone specific alkaline phosphatase and BMD at the TH (p < 0.05).

Conclusions

The data suggest that FGF-23 may be associated with parameters implicated in the complications of CKD. Longitudinal studies are required for further clinical evaluation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K et al (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: Improving global outcomes (KDIGO). Kidney Int 69(11):1945–1953

    Article  CAS  PubMed  Google Scholar 

  2. KDIGO (2009) Clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 76(Suppl 113):S22–S49

    Google Scholar 

  3. Kovesdy CP, Kalanter-Zadeh K (2008) Bone and mineral disorders in pre-dialysis CKD. Int Urol Nephrol 40:427–440

    Article  PubMed  Google Scholar 

  4. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD (2006) Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17:1305–1315

    Article  CAS  PubMed  Google Scholar 

  5. Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N (2005) Circulating FGF-23 is regulated by 1alpha, 25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280:2543–2549

    Article  CAS  PubMed  Google Scholar 

  6. Ito M, Sakai Y, Furumoto M, Segawa H, Haito S, Yamanaka S, Nakamura R, Kuwahata M, Miyamoto KI (2005) Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. Am J Physiol Endocrinol Metab 288:E1101–E1109

    Article  CAS  PubMed  Google Scholar 

  7. Yu X, Sabbagh Y, Davis SI, Demay MB, White KE (2005) Genetic dissection of phosphate and vitamin D -mediated regulation of circulating FGF-23 concentrations. Bone 36:971–977

    Article  CAS  PubMed  Google Scholar 

  8. Kazama JJ, Sato F, Omori K, Hama H, Yamamoto S, Maruyama H, Narita I, Gejyo F, Yamashita T, Fukumoto S, Fukagawa M (2005) Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 67:1120–1125

    Article  CAS  PubMed  Google Scholar 

  9. Juppner H (2007) Novel regulators of phosphate homeostasis and bone metabolism. Ther Apher Dial 11(Suppl 1):S3–S22

    Article  CAS  PubMed  Google Scholar 

  10. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M (2005) Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol Jul 16(7):2205–2215

    Article  CAS  Google Scholar 

  11. Westerberg PA, Linde T, Wikstrom B, Ljunggren O, Stridsberg M, Larsson TE (2007) Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant 22(11):3202–3207

    Article  CAS  PubMed  Google Scholar 

  12. Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, Fukagawa M (2004) Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44:250–256

    Article  CAS  PubMed  Google Scholar 

  13. Urena Torres P, Friedlander G, de Vernejoul MC, Silve C, Prie D (2008) Bone mass does not correlate with the serum fibroblast growth factor-23 in hemodialysis patients. Kidney Int 73(1):102–107

    Article  CAS  PubMed  Google Scholar 

  14. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadani R, Juppner H, Wolf M (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359(6):584–592

    Article  CAS  PubMed  Google Scholar 

  15. Menon V, Greene T, Wang X, Pereira AA, Marcovina SM, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ (2005) C-reactive protein and albumin as predictors of all cause and cardiovascular mortality in chronic kidney disease. Kidney Int 68:766–772

    Article  CAS  PubMed  Google Scholar 

  16. Stenvinkel P, Alvestrand A (2002) Inflammation in end-stage renal disease: sources, consequences and therapy. Sem Dial 15:329–337

    Article  Google Scholar 

  17. Sitara D, Kim S, Razzaque MS, Bergwitz C, Taguchi T, Schuler C, Erben RG, Lanske B (2008) Genetic evidence of serum phosphate-independent functions of fgf-23 on bone. PLOS Genetics 4(8):e10000154

    Article  Google Scholar 

  18. Wang H, Yoshiko Y, Yamamoto R, Minamizaki T, Kozai K, Tanne K, Aubin JE, Maeda N (2008) Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 23:939–948

    Article  CAS  PubMed  Google Scholar 

  19. Archibald G, Bartlett W, Brown A, Christie B, Elliott A, Griffith K, Pound S, Rappaport I, Robertson D, Semple Y, Slane P, Whitworth C, Williams B (2007) UK consensus conference on early chronic kidney disease—6 and 7 february 2007. Nephrol Dial Transplant 22(9):2455–2457

    Article  CAS  PubMed  Google Scholar 

  20. Joseph F, Ahmad AM, Ul-Haq M, Durham BH, Whittingham P, Fraser WD, Vora JP (2008) Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis. J Bone Miner Res 23(5):721–729

    Article  CAS  PubMed  Google Scholar 

  21. Quarles LD (2008) Endocrine functions of bone in mineral metabolism. J Clin Invest 118:3820–3928

    Article  CAS  PubMed  Google Scholar 

  22. Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K (2009) Patterns of FGF-23, DMP1 and MEPE expression in patients with chronic kidney disease. Bone. doi:10.1016/j.bone.2009.08.008

    PubMed  Google Scholar 

  23. Daji F, Shiizaki K, Shimada S, Okada T, Kunimoto K, Sakaguchi T, Hatamura I, Shigematsu T (2009) Regulation of fibroblast growth factor 23 production in bone in uremic rats. Nephron 111:61–68

    Article  Google Scholar 

  24. Nishi H, Nii-Kono T, Nakanishi S, Yamazaki Y, Yamashita T, Fukumoto S, Ikeda K, Fujimori A, Fukagawa M (2005) Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract 101(2):94–99

    Article  Google Scholar 

  25. Stubbs J, Liu S, Quarles LD (2007) Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial. 20(4):302–308

    Article  PubMed  Google Scholar 

  26. Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, Gejyo F, Shigematsu T, Fukagawa M (2005) Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 67(3):1171–1178

    Article  CAS  PubMed  Google Scholar 

  27. Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y (2004) FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int. 65(5):1943–1946

    Article  CAS  PubMed  Google Scholar 

  28. Kazama JJ, Sato F, Omori K, Hama H, Yamamoto S, Maruyama H, Narita I, Geyjo F, Yamashita T, Fukumoto S, Fukagawa M (2005) Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int. 67(3):1120–1125

    Article  CAS  PubMed  Google Scholar 

  29. Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M, Nishizawa Y (2007) Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 18:2683–2688

    Article  CAS  PubMed  Google Scholar 

  30. Lavi-Moshayoff V, Silver J, Naveh-Many T (2009) Human PTH gene regulation in vivo using transgenic mice. Am J Physiol Renal Physiol 297:F713–F719

    Article  CAS  PubMed  Google Scholar 

  31. Sato T, Tominaga Y, Ueki T, Goto N, Matsuoka S, Katayama A, Haba T, Uchida K, Nakanishi S, Kazama JJ, Gejyo F, Yamashita T, Fukagawa M (2004) Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 44:481–487

    CAS  PubMed  Google Scholar 

  32. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK (2005) Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes Prac Patterns Study. Kidney Int 67:1179–1187

    Article  CAS  PubMed  Google Scholar 

  33. Toussaint ND, Kerr PG (2007) Vascular calcification and arterial stiffness in chronic kidney disease; implications and management. Nephrology 12:500–509

    Article  PubMed  Google Scholar 

  34. KDIGO (2009) Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 76(Suppl 113):S50–S99

    Google Scholar 

  35. Jean G, Bresson E, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C (2009) Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 24(3):948–955

    Article  CAS  PubMed  Google Scholar 

  36. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFillipi C, Wolf M (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119:2545–2552

    Article  CAS  PubMed  Google Scholar 

  37. Iseki K, Kohagura K (2007) Anemia as a risk factor for chronic kidney disease. Kidney Int 72:S4–S9

    Article  Google Scholar 

  38. Mallamaci F, Tripepi G, Cutrupi S, Malatino LS, Zoccali C (2005) Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction and myocardiopathy in patients with ESRD. Kidney Int 67:2330–2337

    Article  CAS  PubMed  Google Scholar 

  39. Kojima F, Uchida K, Ogawa T, Tanaka Y, Nitta K (2008) Plasma levels of fibroblast growth factor-23 and mineral metabolism in diabetic and non-diabetic patients on chronic hemodialysis. Int Urol Nephrol 40:1067–1074

    Article  CAS  PubMed  Google Scholar 

  40. Tanaka H, Hamano T, Fujii N, Tomida K, Matsui I, Mikami S, Nagasawa Y, Ito T, Moriyama T, Horio M, Imai E, Isaka Y, Rakugi H (2009) The impact of diabetes mellitus on vitamin D metabolism in predialysis patients. Bone. doi:10.1016/j.bone.2009.07.016

    Google Scholar 

  41. Hesse M, Frohlich LF, Zeitz U, Lanske B, Erben RG (2007) Ablation of vitamin D signalling rescues bone, mineral and glucose homeostasis in FGF-23 deficient mice. Matrix Biology 26:75–84

    Article  CAS  PubMed  Google Scholar 

  42. Raggi P, Bellasi A, Ferramosca E, Block GA, Muntner P (2007) Pulse wave velocity is inversely related to vertebral bone density in haemodialysis patients. Hypertension 49:1278–1284

    Article  CAS  PubMed  Google Scholar 

  43. Toussaint ND, Lau KK, Strauss BJ, Kevan R, Polkinghorne KR (2008) Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol Dial Transplant 23:586–593

    Article  PubMed  Google Scholar 

  44. Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, Jüppner H, Salusky IB (2009) Relationship between plasma FGF-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 94(2):511–517

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Chemical Pathology, 5th Floor, North Wing, St Thomas’ Hospital, Lambeth Palace Road, London, SE1 7EH, UK

    P. Manghat, A. S. Wierzbicki & G. Hampson

  2. Department of Clinical Chemistry, Royal Liverpool Hospital, Liverpool, UK

    W. D. Fraser

  3. Department of Nuclear Medicine, Guy’s Hospital, London, UK

    I. Fogelman

  4. Renal Unit, Guy’s Hospital, London, UK

    D. J. Goldsmith

Authors
  1. P. Manghat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. D. Fraser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. S. Wierzbicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Fogelman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. J. Goldsmith
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Hampson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Hampson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Manghat, P., Fraser, W.D., Wierzbicki, A.S. et al. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int 21, 1853–1861 (2010). https://doi.org/10.1007/s00198-009-1142-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-009-1142-4

Keywords

Search

Navigation